Current NIA Corporate Members in alphabetical order:

Orchid Chemicals and Pharmaceuticals

Orchid Chemicals & Pharmaceuticals Ltd (Orchid) was established in 1992 as a 100% Export Oriented Unit (EOU). Commencing operations in 1994, Orchid has achieved rapid growth to emerge among the Top-15 companies in the Indian pharmaceutical industry in a short span of twelve years of operations. Orchid employs over 3200 people, of which over 600 are scientists, technologists and other professionals.
Orchid is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well as in drug discovery. From the very inception, Orchid has been investing aggressively for establishing modern research and manufacturing facilities aimed at global markets, thus emerging as a world-class pharmaceutical company covering the entire value chain from “Discovery to Delivery”.

Orchid has two manufacturing sites for APIs (at Alathur near Chennai and at Aurangabad, near Mumbai) and three manufacturing sites for Dosage forms (at Irungattukottai and Alathur in Chennai), besides two R&D centres (at Sholinganallur and Irungattukottai). Orchid’s facilities are state-of-the-art and have several international regulatory approvals, including the US FDA and UK MHRA. Orchid’s API facilities are ISO certified for their quality, environmental management and operational health and safety systems. Orchid has a Joint Venture in China for manufacturing sterile APIs.

Orchid’s scientific and technical strengths have made it a partner of choice for several multinational corporations. Orchid has long-term exclusive marketing alliances with reputed global companies such as Apotex, Actavis, Dava and Hospira for distribution of Orchid’s products in the advanced markets of US and Europe.
Orchid's drug discovery activities are channeled through two subsidiaries, Orchid Research Laboratories in Chennai and Bexel Pharmaceuticals in the US. These subsidiaries focus on developing new chemical entities in six therapeutic areas. One lead in the anti-diabetic segment has progressed well and is currently undergoing advanced human clinical trials in Europe. In addition to reducing blood glucose levels in diabetic patients, this novel molecule has also shown indications of hyperlipidemia and hypertension control. Unlike other diabetes drugs it has no adverse effects on liver enzymes and does not lead to weight gain. Besides this, Orchid has lead compounds in various stages of evaluation.

Orchid is a leader in the use of environment friendly technologies. Orchid has invested substantially in zero-discharge manufacturing processes at its facilities and is considered a national show-case in environmental friendliness.

 

Contact:
S. Sritharan
Research Scientist
e: sritharans@orchidpharma.com

For more information, visit the Orchid Pharma website.